<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Our laboratory has found <z:mp ids='MP_0003121'>genomic imprinting</z:mp> of a large genomic domain of human 11p15.5, identifying six imprinted genes within this domain: (a) insulin-like growth factor II (IGF-II), an important autocrine growth factor in a wide variety of <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>; (b) H19, an untranslated <z:chebi fb="40" ids="33697">RNA</z:chebi> that is a putative growth suppressor gene regulating IGF-II; (c) p57KIP2, a cyclin-dependent kinase inhibitor that causes G1-S arrest; (d) KvLQT1, a voltage-gated <z:chebi fb="120" ids="26216">potassium</z:chebi> channel; (e) TSSC3, a gene that is homologous to mouse TDAG51, which is implicated in Fas-mediated <z:mpath ids='MPATH_3'>apoptosis</z:mpath>; and (f) TSSC5, a putative transmembrane protein-encoding gene </plain></SENT>
<SENT sid="1" pm="."><plain>We hypothesize that 11p15 harbors a large domain of imprinted growth-regulatory genes that are important in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Several lines of evidence support this hypothesis: (a) we have discovered a novel genetic alteration in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, loss of imprinting, which affects several of these genes, and is one of the most common genetic changes in human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>; (b) we have found that the <z:e sem="disease" ids="C0019247" disease_type="Disease or Syndrome" abbrv="">hereditary disorder</z:e> <z:e sem="disease" ids="C0004903" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Beckwith-Wiedemann syndrome</z:e>, which predisposes to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and causes prenatal <z:hpo ids='HP_0001548'>overgrowth</z:hpo>, involves alterations in p57KIP2, IGF-II, H19, and KvLQT1; (c) we have found both genetic (<z:hpo ids='HP_0001428'>somatic mutation</z:hpo> in <z:e sem="disease" ids="C0027708" disease_type="Neoplastic Process" abbrv="">Wilms' tumor</z:e>) and epigenetic alterations (DNA methylation) in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>; and (d) we can partially reverse <z:mp ids='MP_0003787'>abnormal imprinting</z:mp> using an inhibitor of DNA methylation </plain></SENT>
<SENT sid="3" pm="."><plain>We propose a model of <z:mp ids='MP_0003121'>genomic imprinting</z:mp> as a dynamic developmental process involving a chromosomal domain </plain></SENT>
<SENT sid="4" pm="."><plain>According to this model, <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> involves both genetic and epigenetic mechanisms affecting this imprinted domain and the genes within it </plain></SENT>
</text></document>